Histogenics (HSGX) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Histogenics Corporation Announces Second Quarter 2017 Financial and Operating Results
August 10, 2017 6:30 AM EDTCompleted Enrollment in NeoCart® Phase 3 Clinical Trial Top-line Data and Potential BLA Filing Expected in Third Quarter of 2018 Defined Regulatory Pathway with Japan Pharmaceuticals and Medical Devices Agency Market Research in U.S. and Japan Points to Potential Large Markets with Significant Unmet Need
WALTHAM, Mass., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced its financial and operational results for the quarter ended June 30, 2017.Â
We achieved a... More
